Somagenetix is a spin-off from the University of Zurich leveraging scientific, clinical & commercial expertise to solve unmet medical needs.

With our gene therapy platform, we aim at becoming a leading company with first & best-in-class treatments for phagocyte-related disorders.

Products, services, technology

We focus on high unmet medical need, devastating diseases with high morbidity, mortality & limited treatment options.

Phagocure our gene therapy platform allows targeted & safe CURE a wide range of immunodeficiencies (lead program), neurological, neuro-metabolic & phagocytes related diseases.

Cooperation possibilities
  • Series A financing round successfully completed- interested in meeting investors
  • Open to strategic partnering - interested in meeting Pharma & Biotech to leverage internal R&D capabilities and deliver synergies for both companies.
Some insights
Location
Canton
Facts & figures
  • Type of organization
    Private company
  • Year of foundation
    2019
  • Number of employees in Switzerland
    1-9
Key business

You may also be interested in